ECO Animal Health Group (LSE:EAH) has unveiled plans for the European launch of its ECOVAXXIN® MS poultry vaccine, following marketing authorisation from the European Commission received in late 2025.
The vaccine is designed to protect layer and breeder chickens against Mycoplasma synoviae, a disease linked to lesions and reduced egg production. With the addition of ECOVAXXIN® MS, the company aims to expand its offering beyond treatment into prevention, complementing its established Mycoplasma therapy Aivlosin® and positioning ECO Animal Health as a comprehensive solutions provider in this segment.
The company intends to utilise its existing European commercial infrastructure alongside newly secured strategic distribution agreements to reach key poultry-producing regions. These markets collectively account for more than 220 million layer birds each year across the EU.
Management plans a phased commercial rollout beginning with distributor education and training programmes, followed by a formal product launch event in Madrid scheduled for mid-2026. Regional introductions will continue through early 2027. ECO Animal Health expects the vaccine to contribute positively to margins shortly after launch, with a meaningful EBITDA impact anticipated in the 2027/28 financial year as adoption builds.
The launch is expected to strengthen the company’s competitive standing within the poultry health market, broadening its revenue mix and supporting longer-term growth ambitions.
ECO Animal Health’s overall stock score reflects strong technical momentum and supportive corporate developments, suggesting investor optimism around future expansion. However, elevated valuation levels and uneven financial performance remain factors that could present risks should projected growth fail to materialise.
More about ECO Animal Health
ECO Animal Health Group is a UK-based global animal health company specialising in branded veterinary pharmaceuticals, with a primary focus on antibiotics and vaccines for pigs and poultry. The business employs more than 200 staff worldwide and holds marketing authorisations in over 70 countries. Its flagship product, Aivlosin®, is widely used to treat respiratory and intestinal diseases affecting pigs and poultry and remains the company’s core commercial asset.
Leave a Reply